WO2015001358A1 - Drug combination and its use in therapy of obesity and type ii diabetes - Google Patents
Drug combination and its use in therapy of obesity and type ii diabetes Download PDFInfo
- Publication number
- WO2015001358A1 WO2015001358A1 PCT/GB2014/052048 GB2014052048W WO2015001358A1 WO 2015001358 A1 WO2015001358 A1 WO 2015001358A1 GB 2014052048 W GB2014052048 W GB 2014052048W WO 2015001358 A1 WO2015001358 A1 WO 2015001358A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- obesity
- diabetes
- pyridinyloxy
- pyrazinyl
- piperazine
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract description 19
- 235000020824 obesity Nutrition 0.000 title claims abstract description 19
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 12
- 239000000890 drug combination Substances 0.000 title description 3
- 238000002560 therapeutic procedure Methods 0.000 title description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960003105 metformin Drugs 0.000 claims abstract description 21
- NPTIPEQJIDTVKR-STQMWFEESA-N vabicaserin Chemical compound C1CNCC2=CC=CC3=C2N1C[C@@H]1CCC[C@@H]13 NPTIPEQJIDTVKR-STQMWFEESA-N 0.000 claims abstract description 15
- 206010033307 Overweight Diseases 0.000 claims abstract description 14
- 229950009968 vabicaserin Drugs 0.000 claims abstract description 14
- DNZVDSXVCHUOFL-CYBMUJFWSA-N 2-[(2r)-2-methylpiperazin-1-yl]-3-(2-pyridin-3-yloxyethoxy)pyrazine Chemical compound C[C@@H]1CNCCN1C1=NC=CN=C1OCCOC1=CC=CN=C1 DNZVDSXVCHUOFL-CYBMUJFWSA-N 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 230000036772 blood pressure Effects 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 230000035488 systolic blood pressure Effects 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
- 230000009467 reduction Effects 0.000 description 18
- 239000002485 serotonin 2C agonist Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- 235000020825 overweight Nutrition 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 238000003801 milling Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- -1 troches Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000004150 EU approved colour Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000007859 condensation product Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000011970 concomitant therapy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- This invention relates to a drug combination, its composition and its use 5 in the treatment of a disease or condition selected from obesity, overweight and type II diabetes.
- Suitable 5HT 2 c agonists of formula (I) for use in the present invention are disclosed in WO00/76984, where they are defined in claims 1 to 41 .
- the compound of formula (I) is (2R)- Methyl-1 - ⁇ 3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl ⁇ piperazine also known as P following structure:
- pharmaceutically acceptable salt is L-malate.
- the synthesis and medical use of PRX933, and salt forms thereof, is disclosed in WO00/76984 (PCT/SEOO/01017) and WO2004/000829 (PCT/SE2003/001043). The content of both documents is hereby incorporated by reference.
- the 5HT 2 c agonist is vabicaserin (9aR,12aS)- 4,5,6,7,9,9a,10,1 1 , 12,12a-decahydrocyclopenta[c][1 ,4]diazepino[6,7,1 - ij]quinoline), which has the following structural formula:
- the present invention makes available a product comprising (i) a 5HT 2 c agonist of formula (I) or vabicaserin and (ii) metformin as a combined preparation for simultaneous, sequential or separate use in treating a disease or condition selected from obesity, overweight and type 2 diabetes.
- the present invention makes available a 5HT 2C agonist of formula (I) or vabicaserin for use in treating a disease or condition selected from obesity, overweight and type 2 diabetes wherein metformin is administered simultaneously, separately or sequentially with the 5HT 2 c agonist of formula (I) or vabicaserin.
- the present invention makes available a method of preventing or treating a disease or condition selected from obesity, overweight and type 2 diabetes, comprising administering to a human or animal subject in need thereof a 5HT 2C agonist of formula (I) or vabicaserin and metformin in sufficient amounts to provide a therapeutic effect.
- the initial reduction in blood pressure will be about 1 to 20 mmHg, preferably from 3 to 15 mmHg such as from 5 to 12 mmHg, from 5 to 10 mmHg, or from 7 to 9 mmHg. In an embodiment the initial reduction in blood pressure is at least 8mmHg. It is expected that the initial reduction in blood pressure will occur within 14 days of commencing treatment. It is expected that this surprising initial (acute) reduction in blood pressure will then be followed by a more gradual reduction as a consequence of weight loss.
- the patient's systolic blood pressure is reduced by greater than 3mmHg within 14 days of starting treatment.
- the patient's blood pressure is reduced by greater than 4mmHg within 14 days of starting treatment.
- the patient's blood pressure is reduced by greater than 5mmHg within 14 days of starting treatment.
- the patient's blood pressure is reduced by greater than 6mmHg within 14 days of starting treatment.
- the term "obesity” is taken to mean the medical condition in which excess body fat has accumulated to the extent that it may have an adverse effect on health, leading to reduced life expectancy and/or increased health problems.
- Body mass index (BMI), a measurement which compares weight and height, defines people as overweight (pre-obese) if their BMI is between 25 and 30 kg/m 2 , and obese when it is greater than 30 kg/m 2 .
- diabetes is taken to mean a metabolic disease in which a person has high blood sugar, either because the body does not produce enough insulin, or because cells do not respond to the insulin that is produced. This is a debilitating disease, being one of the major causes of blindness and kidney failure.
- hypotension is taken to mean a persistently elevated blood pressure i.e. systolic blood pressure greater than 140mmHg and diastolic blood pressure greater than 90mmHg.
- any suitable form of the 5HT 2 c agonist or metformin can be used. These include salts, prodrugs and active metabolites. Suitable dose ranges for the 5HT 2 c agonist or metformin are known in the art, although the synergistic effect of the combination means that the effective dose may be reduced.
- the dose of metformin that is administered with the 5HT 2 c agonist will of course depend on the usual factors, including its potency, but is preferably at least 0.1 , e.g. at least 5, and may be up to 30 mg/kg/day. In an embodiment the dose of metformin is from 1 to 30 mg/kg/day. In another embodiment the dose is from 5 to 20 mg/kg/day. In another embodiment the dose is from 5 to 15 mg/kg/day.
- the dose of the 5HT 2 c agonist that is administered with metformin will of course depend on the usual factors, including its potency, but is preferably at least 0.01 , e.g. at least 0.02, and may be up to 0.3 mg/kg/day.
- the dose of the 5HT 2C agonist is from 0.01 to 0.1 mg/kg/day.
- the dose is from 0.01 to 0.2 mg/kg/day.
- the dose is from 0.05 to 0.3 mg/kg/day.
- the dose is from 0.1 to 0.5 mg/kg/day.
- the compounds of the invention may be administered by any available route, such as via the oral, inhaled, intranasal, sublingual, intravenous, rectal and vaginal routes.
- the oral route is the preferred route of administration.
- the compounds of the invention are preferably formulated as combinations to be administered orally, for example as tablets, troches, lozenges, aqueous or oral suspensions, dispersible powders or granules.
- Preferred pharmaceutical compositions of the invention are tablets and capsules.
- Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
- the pharmaceutical composition of the combination is a pressed tablet or capsule with conventional excipients, examples of which are given below. These may be immediate release or modified, sustained or controlled release preparations.
- compositions of the combination intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
- Tablets contain the combined active ingredients in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients may include, but are not restricted to, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch or alginic acid; binding agents, for example starch gelatin, acacia, microcrystalline cellulose or polyvinyl pyrrolidone; and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate, or glyceryl distearate may be employed.
- Aqueous suspensions may contain the combined active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long- chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids, for example polyoxyethylene sorbitan monooleate.
- suspending agents for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl pyrrolidone, gum tragacanth and
- the aqueous suspensions may also contain one or more preservatives, for example ethyl or n- propyl p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, polyoxyethylene hydrogenated castor oil, fatty acids such as oleic acid, or in a mineral oil such as liquid paraffin or in other surfactants or detergents.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents, such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the combined active ingredients in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable sweetening, flavouring and colouring agents may also be present.
- the combined pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin, or mixtures of these.
- Suitable emulsifying agents may be naturally occurring gums, for example gum acacia or gum tragacanth, naturally occurring phosphatides, for example soya bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening and flavouring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavouring and colouring agents.
- sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative, flavouring and colouring agents.
- Suspensions and emulsions may contain a carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
- a carrier for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
- the 5HT 2 c agonist of formula (I) or vabicaserin in combination with metformin is to be administered via the oral route.
- Combined compositions according to the invention may be produced using conventional formulation techniques.
- spray-drying may be used to produce microparticles comprising the active agent dispersed or suspended within a material that provides the controlled release properties.
- the process of milling may also be used to formulate the therapeutic composition.
- the manufacture of fine particles by milling can be achieved using conventional techniques.
- milling is used herein to refer to any mechanical process which applies sufficient force to the particles of active material to break or grind the particles down into fine particles.
- Various milling devices and conditions are suitable for use in the production of the compositions of the invention.
- the selection of appropriate milling conditions, for example, intensity of milling and duration, to provide the required degree of force, will be within the ability of the skilled person.
- Ball milling is a preferred method.
- a high pressure homogeniser may be used, in which a fluid containing the particles is forced through a valve at high pressure, producing conditions of high shear and turbulence.
- Suitable homogenisers include the EmulsiFlex high pressure homogeniser, the Niro Soavi high pressure homogeniser and the Microfluidics Microfluidiser.
- the milling process can be used to provide the microparticles with mass median aerodynamic diameters as specified above. If hygroscopic, the active agent may be milled with a hydrophobic material, as stated above. If it is required, the microparticles produced by the milling step can then be formulated with an additional excipient. This may be achieved by a spray- drying process, e.g. co-spray-drying. In this embodiment, the particles are suspended in a solvent and co-spray-dried with a solution or suspension of the additional excipient. Preferred additional excipients include polysaccharides. Additional pharmaceutically effective excipients may also be used.
- compositions of the combination intended for inhaled, topical, intranasal, intravenous, sublingual, rectal and vaginal use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions.
- Therapy according to the invention may be conducted in generally known manner, depending on various factors, such as the sex, age or condition of the patient, and the existence or otherwise of one or more concomitant therapies.
- the patient population may be important.
- the present invention is based at least in part on the following studies.
- FIG. 1 shows a graph of the change in supine systolic blood pressure in patients taking (2R)-Methyl-1 - ⁇ 3-[2-(3-pyridinyloxy)ethoxy]-2- pyrazinyl ⁇ piperazine.
- the reduction in blood pressure after 2 weeks (filled bars) and 8 weeks (hatched bars) dosing is plotted against Cmax.
- Asterisks indicate significantly (P ⁇ 0.05) different from placebo (t test).
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A product comprising: (i) (2R)-Methyl-1-{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine or vabicaserin, and (ii) metformin as a combined preparation for simultaneous, sequential or separate use in treating a disease or condition selected from obesity, overweight and type II diabetes.
Description
DRUG COMBINATION AND ITS USE IN THERAPY OF OBESITY AND TYPE II DIABETES
Field of the Invention
This invention relates to a drug combination, its composition and its use 5 in the treatment of a disease or condition selected from obesity, overweight and type II diabetes.
Background of the Invention
Over-weight and obesity are growing problems in the world population,
10 especially in North America and Europe
[http://www.cdc.gov/obesity/data/adult.html]. It is known that patients suffering from obesity have an increased risk of developing diabetes, especially type 2 diabetes [Prevalence and Trends in Obesity Among US Adults, 1999-2000 Regal, KM; Carroll, MD; Ogden, CL; Johnson, CL JAMA. (2002) 288, 1723-
15 1727]. Therefore there is a growing unmet medical need for new medications useful for treating the symptoms, or the underlying causes, of conditions or diseases relating to overweight and obesity, such as type 2 diabetes.
Summary of the Invention
20 In preliminary experimental studies it has been surprisingly found that a combination of (i) a 5HT2C agonist selected from a compound of formula (I) and (ii) the diabetes treatment metformin shows a synergistic effect in reducing appetite in a suitable animal model. The preliminary studies indicate that the effect of the 5HT2c agonist of formula (I) combined with metformin is surprisingly
25 potent and greater than the sum of the individual drugs, suggesting that the combination has a substantially improved effect in reducing appetite, and therefore in the treatment of obesity. One advantage of this combination treatment is that it is possible to reduce the doses of the components and still realise effective appetite reduction thereby further reducing the likelihood of side
30 effects.
Consequently, a considerably reduced dose of both drugs can be given for an equivalent effect for each individual drug, thus reducing side-effects and drug burden while maintaining efficacy.
Suitable 5HT2c agonists of formula (I) for use in the present invention are disclosed in WO00/76984, where they are defined in claims 1 to 41 .
In an embodiment of the invention the compound of formula (I) is (2R)- Methyl-1 -{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine also known as P following structure:
pharmaceutically acceptable salt is L-malate. The synthesis and medical use of PRX933, and salt forms thereof, is disclosed in WO00/76984 (PCT/SEOO/01017) and WO2004/000829 (PCT/SE2003/001043). The content of both documents is hereby incorporated by reference.
In an alternative embodiment the 5HT2c agonist is vabicaserin (9aR,12aS)- 4,5,6,7,9,9a,10,1 1 , 12,12a-decahydrocyclopenta[c][1 ,4]diazepino[6,7,1 - ij]quinoline), which has the following structural formula:
All pharmaceutically acceptable salt forms of vabicaserin are suitable for use in the present invention. Accordingly, the present invention makes available a product comprising (i) a 5HT2c agonist of formula (I) or vabicaserin and (ii) metformin as a combined preparation for simultaneous, sequential or separate use in treating a disease or condition selected from obesity, overweight and type 2 diabetes.
In another embodiment, the present invention makes available a 5HT2C agonist of formula (I) or vabicaserin for use in treating a disease or condition selected from obesity, overweight and type 2 diabetes wherein metformin is administered simultaneously, separately or sequentially with the 5HT2c agonist of formula (I) or vabicaserin.
In another embodiment, the present invention makes available a method of preventing or treating a disease or condition selected from obesity, overweight and type 2 diabetes, comprising administering to a human or animal subject in need thereof a 5HT2C agonist of formula (I) or vabicaserin and metformin in sufficient amounts to provide a therapeutic effect.
In a further aspect of the invention, preliminary studies surprisingly indicate that patients treated with the claimed combination of a 5HT2c agonist of formula (I) or vabicaserin and metformin will experience a reduction in blood pressure which is greater than would be expected from weight loss alone. This unexpected initial reduction in systolic blood pressure occurs within 14 days of starting dosing. It is expected that this initial reduction will then be followed by a further reduction as a consequence of weight loss. This surprising reduction in blood pressure makes the claimed combination especially useful in the treatment of overweight, obesity and/or diabetes in patients suffering from hypertension. It is expected that the initial reduction in blood pressure will be about 1 to 20 mmHg, preferably from 3 to 15 mmHg such as from 5 to 12 mmHg, from 5 to 10 mmHg, or from 7 to 9 mmHg. In an embodiment the initial reduction in blood pressure is at least 8mmHg. It is expected that the initial reduction in blood pressure will occur within 14 days of commencing treatment. It is expected that this surprising initial (acute) reduction in blood pressure will then be followed by a more gradual reduction as a consequence of weight loss. It is expected that within 14 days of starting treatment with the claimed combination of PRX933 or vabicaserin and metformin patients will experience an initial reduction in blood pressure wherein the patient's systolic blood pressure is reduced by greater than 3mmHg within 14 days of starting treatment. In an embodiment the patient's blood pressure is reduced by greater than 4mmHg within 14 days of starting treatment. In an embodiment the patient's blood pressure is reduced by greater than 5mmHg within 14 days of starting treatment. In an embodiment the
patient's blood pressure is reduced by greater than 6mmHg within 14 days of starting treatment.
Description of the Invention
As used herein, the term "obesity" is taken to mean the medical condition in which excess body fat has accumulated to the extent that it may have an adverse effect on health, leading to reduced life expectancy and/or increased health problems. Body mass index (BMI), a measurement which compares weight and height, defines people as overweight (pre-obese) if their BMI is between 25 and 30 kg/m2, and obese when it is greater than 30 kg/m2.
As used herein, the term "diabetes" is taken to mean a metabolic disease in which a person has high blood sugar, either because the body does not produce enough insulin, or because cells do not respond to the insulin that is produced. This is a debilitating disease, being one of the major causes of blindness and kidney failure.
As used herein, the term "hypertension" is taken to mean a persistently elevated blood pressure i.e. systolic blood pressure greater than 140mmHg and diastolic blood pressure greater than 90mmHg.
Any suitable form of the 5HT2c agonist or metformin can be used. These include salts, prodrugs and active metabolites. Suitable dose ranges for the 5HT2c agonist or metformin are known in the art, although the synergistic effect of the combination means that the effective dose may be reduced.
The dose of metformin that is administered with the 5HT2c agonist will of course depend on the usual factors, including its potency, but is preferably at least 0.1 , e.g. at least 5, and may be up to 30 mg/kg/day. In an embodiment the dose of metformin is from 1 to 30 mg/kg/day. In another embodiment the dose is from 5 to 20 mg/kg/day. In another embodiment the dose is from 5 to 15 mg/kg/day.
The dose of the 5HT2c agonist that is administered with metformin will of course depend on the usual factors, including its potency, but is preferably at least 0.01 , e.g. at least 0.02, and may be up to 0.3 mg/kg/day. In an embodiment the dose of the 5HT2C agonist is from 0.01 to 0.1 mg/kg/day. In another embodiment the dose is from 0.01 to 0.2 mg/kg/day. In another embodiment the
dose is from 0.05 to 0.3 mg/kg/day. In another embodiment the dose is from 0.1 to 0.5 mg/kg/day.
The compounds of the invention may be administered by any available route, such as via the oral, inhaled, intranasal, sublingual, intravenous, rectal and vaginal routes. The oral route is the preferred route of administration.
The compounds of the invention are preferably formulated as combinations to be administered orally, for example as tablets, troches, lozenges, aqueous or oral suspensions, dispersible powders or granules. Preferred pharmaceutical compositions of the invention are tablets and capsules. Liquid dispersions for oral administration may be syrups, emulsions and suspensions. More preferably, the pharmaceutical composition of the combination is a pressed tablet or capsule with conventional excipients, examples of which are given below. These may be immediate release or modified, sustained or controlled release preparations.
Compositions of the combination intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the combined active ingredients in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may include, but are not restricted to, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch or alginic acid; binding agents, for example starch gelatin, acacia, microcrystalline cellulose or polyvinyl pyrrolidone; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate, or glyceryl distearate may be employed.
Aqueous suspensions may contain the combined active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium
carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long- chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids, for example polyoxyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl or n- propyl p-hydroxybenzoate, one or more colouring agents, one or more flavouring agents, and one or more sweetening agents, such as sucrose or saccharin.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, polyoxyethylene hydrogenated castor oil, fatty acids such as oleic acid, or in a mineral oil such as liquid paraffin or in other surfactants or detergents. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the combined active ingredients in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable sweetening, flavouring and colouring agents may also be present.
The combined pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin, or mixtures of these. Suitable emulsifying agents may be naturally occurring gums, for example gum acacia or gum tragacanth, naturally occurring phosphatides, for example soya bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate and condensation products of the said partial esters with ethylene oxide, for example
polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, flavouring and colouring agents.
Suspensions and emulsions may contain a carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
In a preferred embodiment, the 5HT2c agonist of formula (I) or vabicaserin in combination with metformin is to be administered via the oral route. Combined compositions according to the invention may be produced using conventional formulation techniques. In particular, spray-drying may be used to produce microparticles comprising the active agent dispersed or suspended within a material that provides the controlled release properties.
The process of milling, for example jet milling, may also be used to formulate the therapeutic composition. The manufacture of fine particles by milling can be achieved using conventional techniques. The term "milling" is used herein to refer to any mechanical process which applies sufficient force to the particles of active material to break or grind the particles down into fine particles. Various milling devices and conditions are suitable for use in the production of the compositions of the invention. The selection of appropriate milling conditions, for example, intensity of milling and duration, to provide the required degree of force, will be within the ability of the skilled person. Ball milling is a preferred method. Alternatively, a high pressure homogeniser may be used, in which a fluid containing the particles is forced through a valve at high pressure, producing conditions of high shear and turbulence. Shear forces on the particles, impacts between the particles and machine surfaces or other particles, and cavitation due to acceleration of the fluid, may all contribute to the fracture of the particles. Suitable homogenisers include the EmulsiFlex high pressure homogeniser, the Niro Soavi high pressure homogeniser and the Microfluidics Microfluidiser. The milling process can be used to provide the microparticles with mass median aerodynamic diameters as specified above. If hygroscopic, the active agent may be milled with a hydrophobic material, as stated above.
If it is required, the microparticles produced by the milling step can then be formulated with an additional excipient. This may be achieved by a spray- drying process, e.g. co-spray-drying. In this embodiment, the particles are suspended in a solvent and co-spray-dried with a solution or suspension of the additional excipient. Preferred additional excipients include polysaccharides. Additional pharmaceutically effective excipients may also be used.
Compositions of the combination intended for inhaled, topical, intranasal, intravenous, sublingual, rectal and vaginal use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions.
Therapy according to the invention may be conducted in generally known manner, depending on various factors, such as the sex, age or condition of the patient, and the existence or otherwise of one or more concomitant therapies. The patient population may be important.
The present invention is based at least in part on the following studies.
Study 1
The preliminary experimental studies indicate that combinations of (i) (2R)-Methyl-1 -{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine and (ii) metformin have significantly improved efficacy in appetite control in animals when compared to (2R)-Methyl-1 -{3-[2-(3-pyridinyloxy)ethoxy]-2- pyrazinyl}piperazine monotherapy and metformin monotherapy.
(2R)-Methyl-1 -{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine (6 mg p.o.) was dosed over a 6h period to a group of 9 normal weight rats fed ad libitum. Metformin (200mg p.o.) was dosed over a 6h period to a separate group of 9 normal weight rats fed ad libitum. Neither dose levels had a significant effect on food intake over a 6h period. However when (2R)-Methyl-1 -{3-[2-(3- pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine (6 mg p.o.) and Metformin (200mg p.o.) were dosed in combination a significant (p<0.01 ) 32.5 ± 5.1 % reduction in food intake over the same time period was observed.
Study 2
The preliminary clinical studies in obese and overweight patients indicate that dosing with (2R)-Methyl-1 -{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine caused a surprising initial reduction in blood pressure within 14 days which was
independent of the weight reduction. The surprising initial reduction in blood pressure was followed by a second reduction in blood pressure consequent on a reduction in weight. Figure 1 shows a graph of the change in supine systolic blood pressure in patients taking (2R)-Methyl-1 -{3-[2-(3-pyridinyloxy)ethoxy]-2- pyrazinyl}piperazine. The reduction in blood pressure after 2 weeks (filled bars) and 8 weeks (hatched bars) dosing is plotted against Cmax. Asterisks indicate significantly (P<0.05) different from placebo (t test).
Claims
1 . A product comprising:
(i) (2R)-Methyl-1 -{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine or vabicaserin, and
(ii) metformin
as a combined preparation for simultaneous, sequential or separate use in treating a disease or condition selected from obesity, overweight and type II diabetes.
2. (2R)-Methyl-1 -{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine or vabicaserin for use in treating a disease or condition selected from obesity, overweight and type I I diabetes wherein metformin is administered simultaneously, separately or sequentially with (2R)-Methyl-1 -{3-[2-(3- pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine or vabicaserin.
3. A method of preventing or treating a disease or condition selected from obesity, overweight and type II diabetes, comprising administering to a human or animal subject in need thereof (2R)-Methyl-1 -{3-[2-(3-pyridinyloxy)ethoxy]-2- pyrazinyl}piperazine or vabicaserin and metformin in sufficient amounts to provide a therapeutic effect.
4. A product according to claim 1 , or a compound according to claim 2, or a method according to claim 3 wherein the treatment for overweight obesity, and type II diabetes is administered to a patient suffering from hypertension.
5. A product, compound, or method according to any one of claims 1 to 4 wherein the patient's blood pressure is reduced by greater than 3mmHg within 14 days of starting treatment.
6. A product, compound, or method according to claim 5 wherein the patient's systolic blood pressure is reduced by greater than 3mmHg within 14 days of starting treatment.
7. A product, compound, or method according to any one of claims 1 to 6 comprising (2R)-Methyl-1 -{3-[2-(3-pyridinyloxy)ethoxy]-2-pyrazinyl}piperazine or a pharmaceutically acceptable salt thereof.
8. A product, compound, or method according to claim 7 wherein the pharmaceutically acceptable salt is the L-Malate salt.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1312128.0A GB201312128D0 (en) | 2013-07-05 | 2013-07-05 | Drug combination and its use in therapy |
GB1312128.0 | 2013-07-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015001358A1 true WO2015001358A1 (en) | 2015-01-08 |
Family
ID=49033419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2014/052048 WO2015001358A1 (en) | 2013-07-05 | 2014-07-04 | Drug combination and its use in therapy of obesity and type ii diabetes |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201312128D0 (en) |
WO (1) | WO2015001358A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011060255A1 (en) * | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Reduced mass metformin formulations |
-
2013
- 2013-07-05 GB GBGB1312128.0A patent/GB201312128D0/en not_active Ceased
-
2014
- 2014-07-04 WO PCT/GB2014/052048 patent/WO2015001358A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011060255A1 (en) * | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Reduced mass metformin formulations |
Non-Patent Citations (1)
Title |
---|
NANNA H. JENSEN ET AL: "Therapeutic Potential of 5-HT2C Receptor Ligands", THE SCIENTIFIC WORLD JOURNAL, vol. 10, 1 January 2010 (2010-01-01), pages 1870 - 1885, XP055134709, DOI: 10.1100/tsw.2010.180 * |
Also Published As
Publication number | Publication date |
---|---|
GB201312128D0 (en) | 2013-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1807083B1 (en) | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis | |
US10660865B2 (en) | Cannabidiol for the prevention and treatment of graft-versus-host disease | |
AU2010332495C1 (en) | Therapeutic combinations of theobromine and an antihistamine | |
WO1995017889A1 (en) | Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis | |
WO2016011254A1 (en) | Combinations of antihistamines and leukotriene antagonists and methods of use thereof | |
BG107185A (en) | Method for the preparation of a medicament for treating sexual dysfunction with apomorphine at specified plasma concentration levels | |
US20220168318A1 (en) | Pharmaceutical compositions and methods for treatment of insomnia | |
US10357492B2 (en) | Levosimendan for use in the treatment of motor neuron diseases (E.G. ALS) | |
MX2012006625A (en) | Combination of theobromine with a decongestant and its use for the treatment of cough. | |
JPWO2006003910A1 (en) | Agents for the prevention and / or treatment of Meniere's disease | |
CN113329749A (en) | Combination therapy for the treatment of uveal melanoma | |
US20220233621A1 (en) | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving energy levels and/or alleviating fatigue | |
WO2015001358A1 (en) | Drug combination and its use in therapy of obesity and type ii diabetes | |
JPWO2010087150A1 (en) | Gastric acid secretion inhibitor and potassium channel inhibitor | |
US20100249103A1 (en) | combination treatment | |
WO2021137224A1 (en) | Cannabidiolic acid esters for treating muscular dystrophy | |
WO2015001357A2 (en) | Drug combination and its use in therapy | |
WO2015001359A1 (en) | Drug combination and its use in therapy of obesity | |
TWI794847B (en) | Composition for reducing metabolic syndrome and application thereof | |
JP6087988B2 (en) | Composition for inhibiting nasal secretion | |
CN111565721A (en) | Composition comprising ibrutinib and an alkaloid with enhanced bioavailability | |
TWI735658B (en) | Composition for reducing metabolic syndrome and application thereof | |
CN112807321B (en) | Composition for treating cerebral ischemia reperfusion injury and application thereof | |
US20060128738A1 (en) | Treatment of interstitial cystitis using cannabinoid analogs | |
AU2015201844B2 (en) | Therapeutic Combinations of Theobromine and an Antihistamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14739520 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14739520 Country of ref document: EP Kind code of ref document: A1 |